Insider · SEC Form 4 filer

Ra Capital Management, L.P.

Past buys: 3 of 9 beat

Companies

Where they file as an insider

Bambusa Therapeutics (BBTX) Director, 10% owner Latest filing Nov 2, 2026
LENZ Therapeutics (LENZ) 10% owner Latest filing Oct 29, 2026
Wave Life Sciences (WVE) Director, 10% owner Latest filing Oct 5, 2026
Vor Biopharma (VOR) 10% owner Latest filing Oct 2, 2026
Sionna Therapeutics (SION) Director, 10% owner Latest filing Sep 17, 2026
Parabilis Medicines (PBLS) Director, 10% owner Latest filing Jul 22, 2026
Artiva Biotherapeutics (ARTV) Director, 10% owner Latest filing Jun 26, 2026
Werewolf Therapeutics (HOWL) 10% owner Latest filing Jun 17, 2026

And 9 more companies with older filings.

Track record

Did their buys beat the typical stock?

Open-market buys30
Quarters checked 6 months later9
Beat the typical stock 3 of 9
Quarters too new to check3

3 of 9 checked quarters beat the typical stock. A past record is data, not a forecast.

Bambusa Therapeutics (BBTX) Bought Oct 30–Nov 2, 2026 · $46.6M · 2.95M shares Too new Too new. Its 6-month check uses prices as of Jun 30, 2027.
Parabilis Medicines (PBLS) Bought Jul 20–22, 2026 · $6.92M · 244,593 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Artiva Biotherapeutics (ARTV) Bought Jun 25–26, 2026 · $292K · 32,876 shares Too new Too new. Its 6-month check uses prices as of Dec 31, 2026.
Wave Life Sciences (WVE) Bought Mar 26–30, 2026 · $54.6M · 8.77M shares Behind typical Mar 31, 2026 $7.25 → Sep 30, 2026 $3.70 · −49.0% (typical stock +1.7%)
Bicara Therapeutics (BCAX) Bought Feb 26, 2026 · $4.8M · 300,000 shares Behind typical Mar 31, 2026 $19.89 → Sep 30, 2026 $18.61 · −6.4% (typical stock +1.7%)
Wave Life Sciences (WVE) Bought Nov 13, 2025 · $6.69K · 1,000 shares Behind typical Dec 31, 2025 $17.00 → Jun 30, 2026 $5.81 · −65.8% (typical stock +4.7%)
Evommune (EVMN) Bought Nov 7, 2025 · $20M · 1.25M shares Behind typical Dec 31, 2025 $17.12 → Jun 30, 2026 $13.29 · −22.4% (typical stock +4.7%)
Mineralys Therapeutics (MLYS) Bought Sep 4, 2025 · $30M · 1.18M shares Behind typical Sep 30, 2025 $37.92 → Mar 31, 2026 $27.09 · −28.6% (typical stock −3.4%)
Tyra Biosciences (TYRA) Bought Jun 12–16, 2025 · $1.66M · 163,287 shares Beat typical Jun 30, 2025 $9.57 → Dec 31, 2025 $26.29 · +174.7% (typical stock +2.1%)
Sionna Therapeutics (SION) Bought Feb 10, 2025 · $20.2M · 1.12M shares Beat typical Mar 31, 2025 $10.46 → Sep 30, 2025 $29.41 · +181.2% (typical stock +7.3%)
Nkarta (NKTX) Bought Mar 27, 2024 · $30M · 3M shares Behind typical Mar 31, 2024 $10.81 → Sep 30, 2024 $4.52 · −58.2% (typical stock +3.2%)
ARS Pharmaceuticals (SPRY) Bought Mar 25–27, 2024 · $13.3M · 1.4M shares Beat typical Mar 31, 2024 $10.22 → Sep 30, 2024 $14.50 · +41.9% (typical stock +3.2%)

Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.

Past results. This is data, not advice.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist